Serametrix Partners LICR

Serametrix has partnered with the Ludwig Institute for Cancer Research (LICR). The agreement will combine LICR’s discoveries in tumor immunology with the technologies and commercial capabilities of Serametrix.

Reportedly, the new alliance is expected to enable rapid development and commercialisation of tests that predict and monitor drug response in cancer patients. The serum-based tests, which determine immune reaction to tumor antigens, are of value to clinicians and drug developers alike.

LICR’s flagship antigen, NY-ESO-1 has licensed to Serametrix as part of this agreement which has already shown promise as a predictor of drug response. It was also announced that Serametrix will add to its current array-based services by launching a serum profiling service dedicated solely to NY-ESO-1 antibody detection. This test will have immediate application in the clinical development of novel cancer therapies.

The company said that as part of the deal, LICR is expected to take an equity stake in Serametrix. In another significant move, director of LICR’s New York branch, Lloyd Old, was appointed chairman of the Serametrix Scientific Advisory Board.

Lloyd Old, chairman of the Serametrix Scientific Advisory Board, said: “Immunological monitoring has a vital role to play in cancer therapy. Tumor antigens have already proved valuable as drug targets and this new agreement will ensure they are also exploited as biomarkers for predicting drug response.”

Henry Scott, CEO of Serametrix, said: “Serametrix is pleased to build upon its relationship with the LICR. This alliance represents a significant step towards more targeted cancer treatments.”